Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2217LS (TNX-4800) in healthy volunteers for Lyme disease prevention
NCT04863287Phase 1Completed
- Sponsor
- MassBiologics
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 2217LS in Lyme disease (5 arms), sponsored by MassBiologics. Primary endpoint: Safety and tolerability by number of adverse events reported. Started Feb 2021; status: completed.
02
Drugs
2217LS
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT04863287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863287.